Related Experiment Video

Updated: Jun 26, 2026

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

Atrial fibrillation and renin-angiotensin system

José Luis Serra1, Mario Bendersky

  • 1Departamento de Arritmias, Sanatorio Allende, Córdoba, Argentina.

Therapeutic Advances in Cardiovascular Disease
|January 7, 2009
PubMed

Insights

Atrial Fibrillation (AF), a common arrhythmia, is linked to cardiac overload and atrial remodeling. Blocking the Renin-Angiotensin System (RAS) shows promise in treating AF by targeting its underlying mechanisms.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Pharmacology

Background:

  • Atrial Fibrillation (AF) is a prevalent arrhythmia, particularly in older adults, often exacerbated by cardiac overload.
  • Pathophysiology involves complex re-entry circuits, electrical/structural remodeling, neurovegetative changes, and cytosolic calcium overload.
  • Interstitial atrial fibrosis, driven by Renin-Angiotensin System (RAS) hyperactivity, significantly contributes to AF persistence.

Purpose of the Study:

  • To review the pathophysiological mechanisms of Atrial Fibrillation.
  • To evaluate the anti-arrhythmic effects of Renin-Angiotensin System (RAS) blockade in AF.
  • To explore potential therapeutic strategies for managing AF.

Main Methods:

  • Literature review of Atrial Fibrillation pathophysiology and treatment.
  • Analysis of clinical evidence supporting RAS blockade in AF.
  • Exploration of proposed mechanisms of action for RAS inhibitors.

Main Results:

  • RAS hyperactivity is a key factor in atrial remodeling and fibrosis, promoting AF.
  • Clinical data suggests RAS blockade has anti-fibrillatory effects.
  • Potential mechanisms include direct ion channel modulation, hemodynamic improvement, reduced atrial stretch, and antifibrotic actions.

Conclusions:

  • RAS blockade represents a promising therapeutic approach for Atrial Fibrillation.
  • Further investigation into antialdosterone drugs for AF is warranted.
  • Understanding remodeling mechanisms is crucial for developing effective AF therapies.

Related Concept Videos

Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Hormonal Regulation01:33

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...